Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT Syrup is a fixed-dose combination oral liquid formulation containing the mucolytic agent ambroxol and the second-generation antihistamine cetirizine. Developed and marketed by Caplet India, it is indicated for the symptomatic treatment of productive cough associated with allergic reactions and respiratory tract disorders. Cetirizine acts as a selective antagonist of peripheral histamine H1 receptors, effectively reducing allergy symptoms such as sneezing, runny nose, and itchy eyes. Ambroxol acts as a secretolytic and mucokinetic agent, thinning and loosening viscous mucus in the airways to facilitate expectoration and clear chest congestion. Together, the two active ingredients provide dual-action relief for patients experiencing concurrent cough and allergy symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol + cetirizine.